Navigation Links
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Date:8/19/2007

designed to stimulate cellular immune responses against HER2/neu. HER2/neu is over-expressed in a variety of solid tumors, including breast, colorectal and ovarian cancer. In clinical studies, patients typically received three infusions over a one-month period as a complete course of therapy.

About Breast Cancer

Breast cancer is the most common non-skin cancer among women. The chance of developing invasive breast cancer at some point in a women's life is about 1 in 8 or 13% of women. It is estimated that in 2007 about 178,480 new cases of invasive breast cancer will be diagnosed among women in the United States. Breast cancer is the second leading cause of cancer death in women, exceeded only by lung cancer.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, the efficacy of PROVENGE or sipuleucel-T, the company's lead product candidate to treat men suffering from prostate cancer, the efficacy of NEUVENGE or lapuleucel
'/>"/>

SOURCE Dendreon Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... Segments: Software, Hardware, and Biocontent. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
(Date:9/16/2014)... University scientists who created a deicing film for radar ... a transparent coating for glass. , The new ... could keep glass surfaces from windshields to skyscrapers free ... radio frequencies (RF). , The technology was introduced ... Applied Materials and Interfaces . , The material ...
(Date:9/16/2014)...  The Council for Entrepreneurial Development (CED), the ... country, today released a mid-year update to its ... It showed that in the first half of ... in the technology, life science, advanced manufacturing and ... variety of sources. Significant investment in technology companies and ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23Nanoribbon film keeps glass ice-free 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 2CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 3CED's Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector 4
... Mylan Inc. (NYSE: MYL ),today announced that Mylan ... and Drug Administration (FDA) for its,Abbreviated New Drug Application ... and 200 mg., Lamotrigine Tablets are the generic ... approximately $1.97 billion,for the 12 months ending Sept. 30, ...
... Calif., Dec. 12 LUMEDX Corporation, the ... and imaging,solutions, introduces CardioManager Performance Management System(TM),cardiology ... operational,financial -- into accessible, actionable information. CardioManager,s,performance ... a,high-level view of data and the ability ...
... the FDA for the Fourth Genmab Antibody ... Collaboration with Roche., COPENHAGEN, December 12 Genmab ... application (IND) for a,Genmab antibody developed under the company,s ... Roche. Genentech and Roche are collaborating on,development of the ...
Cached Biology Technology:New Cardiology Software Helps Heart Centers Manage for Optimal Clinical Performance 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3
(Date:9/16/2014)... have discovered the "molecular brakes" that time the generation ... mice. These "hair cells" translate sound waves into electrical ... interpreted as sounds. If the arrangement of the cells ... of the research will be published in The ... proteins Hey1 and Hey2 act as brakes to prevent ...
(Date:9/16/2014)... The meteorite impact that spelled doom for the dinosaurs ... flowering plants to a much greater extent than their ... researchers. The results are published in the journal ... a treasure trove of thousands of fossilized leaves of ... team was able to reconstruct the ecology of a ...
(Date:9/16/2014)... Hesperides vessel returned to Spain culminating the around the ... clear picture of how the global ocean works and ... pollutants from the atmosphere is not limited to coastal ... of the planet, and it is already affecting the ... week in CSIC Residence for Researchers in Barcelona, in ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... seafood, the options are many and so are some of the ... healthy? Is it safe? Is it endangered? While there are many ... an iPhone app a group of researchers have found a ... then it is likely to be healthy to eat too," said ...
... are more common than ever before. According to the ... Americans suffers from an allergy from milder forms ... allergies which can lead to anaphylactic shock. ... an allergic reaction, the treatment is too limited, says ...
... Boulder, Colo., USA Two Geology studies focus on ... view of alpine denudation and the other studying and ... include fossil microatolls and sea level; the potential rupture ... Northwest and British Columbia; paleoclimate; and the relationship between ...
Cached Biology News:Study finds healthy seafood comes from sustainable fish 2What sets allergies in motion? 2What sets allergies in motion? 3Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 2Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 3Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 4Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 5Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 6Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 7Debris flows, landslides, fossil microatolls, paleo-seasonality, and carbonate ore deposits 8